QLF32101

Phase Ia: Main study objectives Evaluate the safety and tolerability, MTD and RP2D of QLF32101 administered intravenously and subcutaneously in R/R and AML patients. Secondary study objectives Observe the pharmacokinetic (PK) characteristics, immunogenicity and preliminary efficacy of QLF32101 administered intravenously and subcutaneously in R/R AML patients; Phase Ib; Main study objectives Evaluate the preliminary efficacy of QLF32101 monotherapy in R/R AML patients and patients with intermediate- and high-risk myelodysplastic syndrome (MDS). Secondary study objectives Evaluate the safety, PK characteristics and immunogenicity of QLF32101 in AML and MDS patients;